Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communitiesAuthor of the article:Ingelheim, Germany GNWRabies remains one of the world’s deadliest yet preventable zoonotic diseases, highlighting the need for sustained prevention efforts.Through a new multi-year collaboration, Boehringer Ingelheim and AWARE are expanding dog vaccination, population management and education efforts in rural Zimbabwe.By protecting animal health, the initiative helps safeguard people, communities, and livelihoods. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountIngelheim, Germany – As part of its global Stop Rabies program, Boehringer Ingelheim, AWARE Germany e.V. and AWARE Trust Zimbabwe are launching a comprehensive rabies-control initiative in the Tsholotsho District of Zimbabwe, one of the most remote and poorest rural areas in the country. Together, the two veterinary-led AWARE organizations follow a holistic One-Health approach to improve animal welfare, community wellbeing, and wildlife conservation. The collaboration with Boehringer Ingelheim combines dog vaccination and population management with education of children to help reduce the burden of rabies in one of the country’s most affected regions. Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againRabies is entirely preventable, yet it continues to claim tens of thousands of lives every year. Rural communities are especially vulnerable, and children are among those most affected. Because more than 99% of human rabies cases originate from infected dogs, vaccinating dogs remains the most effective way to stop the disease at its source and protect both people and animals1. Expanding Stop Rabies in Zimbabwe At the center of the new Stop Rabies project in Zimbabwe is a comprehensive program based at AWARE’s veterinary hub in Tsholotsho. Through mobile veterinary teams, the project aims to vaccinate approximately 15,000 dogs every year, reaching an estimated vaccination coverage of more than 90% of the local dog population. The program also includes the free sterilization of at least 1,200 dogs annually, helping support sustainable rabies control and animal welfare.“No one should die from a disease that can be prevented. Through our Stop Rabies program, we are contributing to eliminating dog-mediated human rabies deaths, knowing that this can only be achieved through collective action,” says Thaïs Vila, Global Program Lead for Stop Rabies at Boehringer Ingelheim. The collaboration builds on AWARE’s longstanding rabies prevention work in Zimbabwe and reflects a shared commitment to protecting interconnected lives. Protecting dogs from rabies is one of the most effective ways to reduce disease transmission, improve human health and strengthen community resilience. “We have seen firsthand how sustained vaccination, and community engagement can reduce the burden of rabies. With Boehringer Ingelheim’s support, we can expand our reach and strengthen local veterinary services to help protect even more communities across Tsholotsho,” says Martin Kessler, Chair of AWARE Germany. Education is another key part of the collaboration. AWARE is expanding its PAWS Clubs (Promoting Animal Welfare Clubs), training 170 teachers across 85 schools and reaching more than 50,000 students with information on rabies prevention, safe interactions with dogs and responsible animal care. This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.Through this collaboration, Boehringer Ingelheim and AWARE are demonstrating how collective action can help protect lives and move communities closer to a future free from dog-mediated rabies. By combining prevention, education and community action, the partnership is helping tackle rabies at its source while building a model that can support long-term progress in affected communities.1 World Health Organization (WHO). Rabies.https://www.who.int/health-topics/rabiesAbout AWARE AWARE Trust Zimbabwe and AWARE Germany e.V. are partner non-governmental organizations dedicated to protecting biodiversity through veterinary outreach, education and wildlife conservation programs. Both organizations are led by veterinarians and work closely with local communities to improve the health and wellbeing of animals, people and ecosystems. Learn more at www.aware-germany.de Boehringer Ingelheim – Animal Health business Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.